1 Arzneimittelinformation der Swissmedic Apranax®
(
www.swissmedicinfo.ch; 21.04.2017)
2 Feldman M. NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity. In: UpToDate, S Grover (Ed), UpToDate, Waltham, MA. (Zugriff am 09.05.2017).
3 Feldman M. NSAIDSs (including aspirin): Primary prevention of gastroduodenal toxicity. In: UpToDate, s Grover (Ed) (Zugriff am 10.05.2017).
4 Vakil N. Peptic ulcer disease: Genetic, environmental, and psychological risk factors and pathogenesis. In: UpToDate, S Grover (Ed) (Zugriff am 09.05.2017).
5 M Cahalane. Overview of gastrointestinal tract perforation. In UpToDate, W Chen (Ed), UpToDate (Zugriff am 09.05.2017).
6 Richy F, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis. 2004;63(7):759.
7 Chan FK, et al. Randomised trial of eradication og Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet. 1997;350(9083):975.
8 D H Solomon. Overview of selective COX-2 inhibitors. In: UpToDate, P Romain (Ed), UpToDate (Zugriff am 09.05.2017).
9 C Scarpignato et al. Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Medicine. 2016;14:179.
10 Nissen S, et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016;375;26:2519–29.
11 Labenz J, et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut. 2002;51(3):329.